Is Codeine Still in Cough Syrup?

Codeine is still an ingredient in some prescription cough syrups, but its availability has narrowed sharply over the past decade. In many countries, it is no longer sold over the counter for cough at all, and prescriptions for codeine-containing cough medicines in the United States dropped by roughly 90 percent between 2014 and 2019. The decline reflects a convergence of weak efficacy evidence, serious safety signals in certain patients, and growing concern about misuse and addiction.

How Codeine Became the “Gold Standard” for Cough

Codeine has been used to suppress cough for well over a century. For most of modern medicine, it was widely regarded as the gold standard cough suppressant, and that reputation shaped both prescribing habits and patient expectations.¹ The drug works by acting on opioid receptors in the brain, dampening the cough reflex. Because it is a weak opioid, it was long assumed to be effective enough to justify the modest risks. That assumption, however, has not held up well under modern scrutiny.

The Evidence Problem

If you look at the clinical trial data behind codeine’s cough-suppressing reputation, the results are surprisingly thin. Several well-designed studies have found that codeine performs no better than a sugar pill when it comes to reducing cough from common respiratory infections.

In children, a randomized trial comparing codeine, dextromethorphan, and placebo for nighttime cough found that neither active drug was significantly more effective than placebo.² The pattern in adults is similar. A comprehensive review of European antitussive medications noted that despite codeine’s widespread use, there is very little clinical evidence supporting meaningful cough suppression from oral codeine. In two studies of cough from upper respiratory infections, codeine at standard doses had no effect greater than placebo syrup, whether measured objectively or by patient self-report.³ A German review of the evidence on acute cough treatment put it bluntly: there is inadequate evidence for the efficacy of antitussive drugs against acute cough.⁴

Part of the reason codeine looked effective for so long has to do with the placebo effect in cough. Cough tends to improve on its own, and studies have documented that a placebo alone can reduce cough by over 60 percent. In acute cough, the placebo response can reach as high as 85 percent.⁵ When a drug has to beat that kind of baseline, it needs a genuinely powerful effect to look any different from doing nothing. Codeine does not appear to have one, at least for the short-term coughs most people experience with colds and upper respiratory infections.

Why Codeine Is Riskier Than Its Reputation Suggests

Codeine itself is actually a weak drug. To produce its main effects, it has to be converted into morphine inside your liver by an enzyme called CYP2D6. How much morphine you end up with depends almost entirely on the genetic variant of that enzyme you carry. This is where things get dangerous for certain people.

People who are “poor metabolizers” have reduced or absent CYP2D6 activity. They convert very little codeine to morphine, which means the drug barely works for them at all.⁶ At the other extreme are “ultrarapid metabolizers,” who carry extra copies of the CYP2D6 gene and convert codeine to morphine far faster and more completely than normal. For these individuals, a standard dose of codeine can flood the body with morphine, leading to potentially life-threatening opioid toxicity.⁷ A case published in the New England Journal of Medicine described a patient who developed life-threatening opioid intoxication from small doses of codeine prescribed for a cough. Genetic testing revealed the patient was an ultrarapid metabolizer, and the combination of rapid morphine production with other medications that slowed its clearance created a perfect storm.⁸

The prevalence of ultrarapid metabolism varies by population. In some ethnic groups, the rate is as high as one in ten people. Since most patients have no idea which metabolizer type they are, every codeine prescription carries some degree of unpredictable risk. This uncertainty is a key reason regulators have tightened access.

How Regulations Have Changed

The regulatory landscape for codeine cough products has shifted substantially in the past decade, particularly for children. In the United States, the FDA issued safety communications in 2017 and 2018 restricting codeine use in patients under 18 for cough and pain. Prescriptions for codeine cough and cold medications to children and adolescents plummeted from about 232,000 in 2014 to roughly 23,000 in 2019, a decline of about 90 percent.⁹ The study that tracked this decline noted that the drop was already well underway before the FDA communications, suggesting that clinical awareness of codeine’s risks was shifting prescribing patterns on its own. The CHEST guideline expert panel recommended avoiding codeine-containing medications for cough in all patients under 18 because of the potential for serious side effects, including respiratory distress.¹⁰

Internationally, the trend is moving in the same direction but unevenly. France and Australia have reclassified codeine so it requires a prescription. In countries like the UK, Ireland, South Africa, Canada, and Switzerland, governments have proposed or are considering similar reclassification of codeine-containing products.¹¹ In parts of the United States, the situation is a patchwork: some states have moved codeine cough syrups behind the pharmacy counter or to prescription-only, while others still allow limited over-the-counter access. For adults, prescription codeine cough syrups remain available in many markets, though doctors are increasingly reluctant to write those prescriptions.

Why Doctors Still Sometimes Prescribe It

Given weak efficacy data and real safety concerns, you might wonder why codeine cough syrup hasn’t simply disappeared. Several factors keep it around. One is clinical inertia: physicians trained in an era when codeine was the default cough suppressant may continue to reach for it out of habit. A study of prescribing behavior in emergency departments found that poor awareness of codeine addiction risk, limited familiarity with updated guidelines, and mistaken assumptions about what patients expect all contributed to continued opioid prescribing.¹² Patients themselves sometimes request codeine by name, believing it is more powerful than over-the-counter alternatives, even though the evidence does not support that belief.

Another factor is chronic cough. While the data on codeine for short-term cough from colds is unimpressive, some clinicians still consider it for chronic, refractory cough when other options have failed. The reasoning is partly that the sedating properties of opioids might provide symptomatic relief even if the cough reflex itself is not being pharmacologically suppressed. This is a controversial use, and newer drugs are beginning to offer a more targeted alternative.

What Has Replaced Codeine

The most common over-the-counter cough suppressant in most countries is dextromethorphan, often abbreviated DXM. It is the active ingredient in products like Robitussin DM and Delsym. A head-to-head comparison found that at equal doses, dextromethorphan was similarly effective to codeine at reducing cough frequency and actually lowered cough intensity to a significantly greater degree. Patients in that study also preferred dextromethorphan overall.¹³ DXM is not an opioid and does not carry the same respiratory depression or addiction risks, though it has its own misuse potential at very high doses.

For prescription alternatives, benzonatate (brand name Tessalon) has surged in popularity. It is the only widely available prescription non-narcotic cough suppressant, and the rate at which it is dispensed has increased rapidly.¹⁴ Benzonatate works differently from opioids, numbing stretch receptors in the lungs and airways. However, a systematic review found substantial limitations in the existing evidence for benzonatate’s safety and effectiveness, noting that its original approval was based on evidence that would not meet current regulatory standards. Overdose and accidental ingestion (especially in children who mistake the gel capsules for candy) have raised growing safety concerns.¹⁵

For children in particular, honey has become a surprisingly well-supported option. A Cochrane review found that honey probably reduces cough frequency better than no treatment or placebo in children, and may perform similarly to dextromethorphan.¹⁶ A separate meta-analysis of upper respiratory infections found that honey improved cough frequency, cough severity, and overall symptom scores compared to usual care.¹⁷ Honey should not be given to infants under one year old because of botulism risk, but for older children and adults with an annoying cough from a cold, a spoonful of honey is backed by better evidence than many pharmacy products. That is a genuinely strange sentence to write, but the data support it.

Cough Syrup Misuse and “Lean”

Codeine cough syrup has a second life outside of medicine. A mixture of codeine-promethazine cough syrup with a soft drink (typically a lemon-lime soda) and sometimes alcohol has been a recreational drug since at least the early 1990s. Known by names like “purple drank,” “lean,” or “sizzurp,” the concoction produces a sedated, euphoric state from the combination of the opioid and antihistamine.¹⁸ The practice gained wide visibility through its promotion in rap music and social media, though research shows that its use is not confined to any single demographic.¹⁹

Lean has become a recognizable cultural symbol, often depicted in the distinctive double Styrofoam cup.²⁰ The health risks are not trivial: respiratory depression from the opioid component, compounded by the sedating effects of promethazine and alcohol, has been linked to multiple deaths. This misuse pattern has been one of the driving forces behind stricter codeine regulations worldwide, particularly the push to remove codeine from over-the-counter availability. When a cough syrup becomes a street drug, the regulatory calculus changes even if the medical conversation is focused on efficacy.

Children and Cough Medicine Safety

The pediatric angle deserves its own attention because the risks are different for kids. Young children are more vulnerable to opioid respiratory depression, and the CYP2D6 metabolizer variability adds another layer of unpredictability. The concern is not limited to codeine: an estimated 7,000 children under 12 are treated in emergency departments each year in the United States for adverse events from cough and cold medications of all kinds. Most of these visits involve children aged two to five, and about two-thirds are from unsupervised ingestions, meaning the child got into the medicine on their own.²¹

This data has pushed professional organizations to recommend against virtually all cough suppressants in young children. For kids under six, the consensus in most guidelines is that no cough medicine has been shown to work, and all of them carry some risk. Honey (for children over age one) and comfort measures like humidified air and fluids are the preferred approaches. For older children and teens, dextromethorphan remains an option, but codeine is now explicitly recommended against in patients under 18 in both U.S. and European guidelines.

Newer Drugs on the Horizon

For people with chronic cough that does not respond to standard treatments, the most significant development in years is a class of drugs called P2X3 receptor antagonists. These target a receptor involved in the hypersensitivity of the cough reflex, a fundamentally different approach from suppressing the brain’s cough center the way opioids attempt to. A meta-analysis of 11 randomized controlled trials found that P2X3 antagonists significantly reduced cough frequency, severity, and impact on quality of life in patients with refractory or unexplained chronic cough.²²

The first of these drugs, gefapixant, is already approved in several countries. Its main downside is taste disturbance: many patients report an altered or reduced sense of taste while taking it. Four newer, more selective P2X3 antagonists are in development specifically to reduce this side effect while preserving the cough-suppressing benefit.²³ These drugs are not aimed at the same population as codeine cough syrup. They are designed for chronic, stubborn coughs that last months or years, not for the acute cough that follows a cold. But they represent the first real mechanistic advance in cough treatment in decades, and they may eventually push codeine further toward obsolescence even in the niche where some doctors still consider it.

Where Codeine Cough Syrup Stands Today

If you walk into a pharmacy looking for a cough suppressant, the answer to “is codeine still in cough syrup” depends heavily on where you live and how old you are. In countries like Australia and France, you will not find it without a prescription. In the UK and parts of Canada, you can still buy low-dose codeine products over the counter, though that access may be on borrowed time as reclassification proposals move forward. In the United States, codeine cough syrups are available by prescription in most states, but the number of those prescriptions has fallen dramatically, especially for anyone under 18.

The bigger picture is that codeine’s place in cough treatment has eroded from nearly every direction at once. The evidence for its effectiveness against cough has always been weaker than people assumed. Its safety profile is complicated by genetic variability that most patients and many prescribers do not think about. Its potential for misuse and addiction has attracted regulatory attention. And alternatives that are at least as effective and considerably safer are readily available over the counter. Codeine cough syrup still exists, but the question of whether it should is one that the medical community has been answering with increasing skepticism for years.